AUTOANTIBODIES IN WOMEN WITH SILICONE BREAST IMPLANTS

硅胶乳房植入物女性体内的自身抗体

基本信息

  • 批准号:
    3149489
  • 负责人:
  • 金额:
    $ 18.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1993
  • 资助国家:
    美国
  • 起止时间:
    1993-09-01 至 1996-08-31
  • 项目状态:
    已结题

项目摘要

Certain "autoimmune" diseases are observed in women who have undergone breast augmentation procedures with encapsulated silicone gel implants. It has, however, not been determined whether this is a cause and effect relationship or whether the auto immune diseases are found in normally expected incidence and prevalence as in the general population. Our own initial studies have shown that antinuclear antibodies are present in up to 90% of women with silicone breast implants who have defined auto immune diseases and that some of the autoantibodies are those which have been recognized in idiopathic forms of scleroderma and lupus while many others remain unidentified. The objective of this proposal is to comprehensively characterize the profiles and fine specificities of autoantibodies in the sera of patients with silicone breast implants. This will be done with techniques which include immunofluorescence microscopy, Western blotting and immunoprecipitation of biosynthetically labelled cells by which antigenic proteins and/or their associated RNAs can be detected. It has already been shown that there are some new antigens reacting with antibodies from patients with silicone breast implants. A number of sera which recognize unknown antigens will be selected as cloning reagents to probe cDNA expression libraries. Analysis of the nucleic acid and protein sequences of the isolated antigens will be used to determine if characteristic structural and functional motifs are present in these antigens since this information might provide leads to their nature. Recombinant antigens will be generated from the cDNA clones and the authenticity of the recombinant proteins verified in ELISA with the original sera used for library screening. It will then be possible with ELISA and screening of large numbers of sera to ascertain whether autoantibodies to these antigens are unique for silicone-associated auto immune diseases or are also present in the idiopathic diseases. If autoantibody profiles and fine specificities are not different from spontaneous autoimmune diseases, the evidence would favor an adjuvant-like effect of silicone in the promotion of what has been called idiopathic autoimmune disease. However, if the profiles and specificities show that although there are certain similarities as has been reported, there are also distinct differences, the evidence would argue that silicone was provoking autoimmune syndromes by additionally different mechanisms from the idiopathic forms of these diseases.
某些“自身免疫性”疾病在经历过 隆胸手术与封装硅凝胶植入物。 然而,还没有确定这是否是因果关系。 关系或自身免疫性疾病是否在正常 与一般人群中的预期发病率和患病率相同。 我们自己 最初的研究表明,抗核抗体存在于 90%的硅胶乳房植入体女性, 疾病和一些自身抗体是那些已经被 在硬皮病和狼疮的特发性形式中被认识到,而许多其他 仍然身份不明 本提案的目的是全面描述 患者血清中自身抗体的谱和精细特异性 硅胶隆胸 这将通过以下技术来完成, 包括免疫荧光显微术、蛋白质印迹法 生物合成标记细胞的免疫沉淀, 可以检测蛋白质和/或其相关的RNA。 它已经 已经表明,有一些新的抗原与来自 硅胶乳房植入体的患者。 一些血清可以识别 选择未知抗原作为克隆试剂, 表达式库。核酸和蛋白质序列分析 分离的抗原将用于确定是否具有特征性 结构和功能基序存在于这些抗原中, 信息可能会提供线索,他们的性质。 重组抗原 将产生的cDNA克隆和真实性的 使用用于检测的原始血清在ELISA中验证重组蛋白 文库筛选 然后将有可能通过ELISA和筛选 大量的血清,以确定是否自身抗体,这些 抗原对于硅酮相关的自身免疫性疾病是独特的, 也存在于特发性疾病中。 如果自身抗体谱和精细特异性与 自发性自身免疫性疾病,证据将有利于 硅胶在促进所谓的特发性 自身免疫性疾病 但是,如果特征和特异性表明, 虽然有某些相似之处,如已报告的, 也有明显的差异,证据表明,硅胶是 引发自身免疫综合征的另外不同的机制, 这些疾病的特发性形式

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eng M TAN其他文献

Eng M TAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eng M TAN', 18)}}的其他基金

MOLECULAR BIOLOGY OF AUTOANTIBODIES
自身抗体的分子生物学
  • 批准号:
    2879627
  • 财政年份:
    1999
  • 资助金额:
    $ 18.71万
  • 项目类别:
AUTOANTIBODIES TO CELLULAR MATRIX ANTIGENS IN CFS
CFS 中细胞基质抗原的自身抗体
  • 批准号:
    2672953
  • 财政年份:
    1997
  • 资助金额:
    $ 18.71万
  • 项目类别:
AUTOANTIBODIES TO CELLULAR MATRIX ANTIGENS IN CFS
CFS 中细胞基质抗原的自身抗体
  • 批准号:
    2005580
  • 财政年份:
    1997
  • 资助金额:
    $ 18.71万
  • 项目类别:
AUTOANTIBODIES TO CELLULAR MATRIX ANTIGENS IN CFS
CFS 中细胞基质抗原的自身抗体
  • 批准号:
    6170028
  • 财政年份:
    1997
  • 资助金额:
    $ 18.71万
  • 项目类别:
AUTOANTIBODIES TO CELLULAR MATRIX ANTIGENS IN CFS
CFS 中细胞基质抗原的自身抗体
  • 批准号:
    2887403
  • 财政年份:
    1997
  • 资助金额:
    $ 18.71万
  • 项目类别:
AUTOANTIBODIES IN WOMEN WITH SILICONE BREAST IMPLANTS
硅胶乳房植入物女性体内的自身抗体
  • 批准号:
    2069757
  • 财政年份:
    1993
  • 资助金额:
    $ 18.71万
  • 项目类别:
AUTOANTIBODIES IN WOMEN WITH SILICONE BREAST IMPLANTS
硅胶乳房植入物女性体内的自身抗体
  • 批准号:
    2069756
  • 财政年份:
    1993
  • 资助金额:
    $ 18.71万
  • 项目类别:
ANTIBODIES AND ANTIGENS IN HEPATOCELLULAR CARCINOMA
肝细胞癌中的抗体和抗原
  • 批准号:
    6686330
  • 财政年份:
    1992
  • 资助金额:
    $ 18.71万
  • 项目类别:
ANTIBODIES AND ANTIGENS IN HEPATOCELLULAR CARCINOMA
肝细胞癌中的抗体和抗原
  • 批准号:
    6831649
  • 财政年份:
    1992
  • 资助金额:
    $ 18.71万
  • 项目类别:
AUTOANTIBODIES IN HEPATOCELLULAR CARCINOMA
肝细胞癌中的自身抗体
  • 批准号:
    2097719
  • 财政年份:
    1992
  • 资助金额:
    $ 18.71万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 18.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了